Cargando…
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
Canakinumab is an anti-interleukin-1β monoclonal antibody approved for use in a range of immune-related disorders. During the clinical investigation (CANTOS trial) for prevention of cardiovascular complications, therapy was linked to a reduction in both the occurrence and mortality of lung cancer. T...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427732/ https://www.ncbi.nlm.nih.gov/pubmed/35739301 http://dx.doi.org/10.1038/s41416-022-01893-5 |